Atropine for myopia control. the past five years have seen research and clinical practice focus on low-concentration atropine (0.01% to 0.05%), which appears to provide dose-related efficacy with minimal side effects, compared to higher concentrations. The use of topical atropine for myopia control has decades of clinical and research history, but recent research has explored low concentrations, different formulations, and whether combination with optical treatments can boost myopia control results. New, preservative-free formulations are now superseding compounded preparations in scientific studies and adding to the story on the ideal concentration and target populations. Follow the links on this page to learn more about atropine for slowing myopia progression. Low-dose atropine for myopia control. Whilst higher doses of atropine can cause blurred vision, lower doses (0.01% to 0.05%) have been shown to have minimal effects on reading vision, making them more attractive options to prescribe for myopia control. Myopia develops when the eye elongates, which causes light to focus in front of the retina rather than directly on it. LAMP studies (low-concentration atropine for myopia progression) showed low-dose atropine slowed eye growth by about 30% to 50%, depending on dosage, making it an effective treatment to slow down progression. This method of myopia control is also very simple to use: Just place one drop in each eye before
bedtime each night—that’s it!